Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright‘s price target would indicate a potential upside of 498.21% from the stock’s previous close. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($15.52) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.90) EPS, Q4 2027 earnings at ($0.97) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($3.10) EPS and FY2030 earnings at ($3.09) EPS.
A number of other research firms have also issued reports on FTH. TD Cowen initiated coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 9th. They set a “buy” rating on the stock. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. Citigroup upped their price objective on Sensei Biotherapeutics from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. William Blair assumed coverage on Sensei Biotherapeutics in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Finally, Guggenheim decreased their target price on Sensei Biotherapeutics from $70.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $56.58.
Check Out Our Latest Report on Sensei Biotherapeutics
Sensei Biotherapeutics Stock Performance
NASDAQ FTH opened at $10.03 on Monday. The firm has a market cap of $259.18 million, a P/E ratio of -0.07 and a beta of -0.14. The firm has a 50-day moving average price of $25.07. Sensei Biotherapeutics has a 1-year low of $7.45 and a 1-year high of $42.14.
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.13). On average, sell-side analysts anticipate that Sensei Biotherapeutics will post -14.01 EPS for the current fiscal year.
Hedge Funds Weigh In On Sensei Biotherapeutics
Hedge funds have recently made changes to their positions in the company. State of Wyoming acquired a new position in Sensei Biotherapeutics during the third quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Sensei Biotherapeutics by 48.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock worth $150,000 after buying an additional 1,760 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics in the second quarter valued at $307,000. Jump Financial LLC acquired a new stake in shares of Sensei Biotherapeutics in the third quarter valued at about $694,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Hedge funds and other institutional investors own 10.50% of the company’s stock.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.
See Also
- Five stocks we like better than Sensei Biotherapeutics
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
